Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Biliary Tract Neoplasms × niraparib × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 9 Neoplasms 2 Fallopian Tube Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Metastatic Castration-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Glioblastoma 1 Carcinoma, Ovarian Epithelial 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 12 Cisplatin 10 durvalumab 7 S 1 (combination) 3 Oxaliplatin 3 Capecitabine 3 zanidatamab 2 gemcitabine-oxaliplatin regimen 2 Trastuzumab 2 Leucovorin 2 trastuzumab deruxtecan 1 pembrolizumab 1 niraparib 1 neratinib 1 ivosidenib 1 futibatinib 1 envafolimab 1 encorafenib 1 binimetinib 1 Tegafur 1 Pancreaticojejunostomy 1 Irinotecan 1 Folfox protocol 1 Fluorouracil 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Carboplatin 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05615818 2025-04-23

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡